In the immuno-oncology field, scientists discover, test, and validate novel immunotherapeutic agents that leverage the human immune system to fight cancer, such as checkpoint inhibitors, vaccine-based ...
When we hear that a person has quirks, we expect to be charmed. But when we hear that a cell-based assay has quirks, we expect to be frustrated. Quirks in cell-based assays tend to complicate drug ...
Gregory Russotti is the Chief Technology and Manufacturing Officer at Century Therapeutics, a company developing iPSC-derived, allogeneic immune cell therapy products for hematology/oncology ...
Whether you're preparing for your first IND or scaling up for commercial release, assay integrity is non-negotiable. This white paper reflects our commitment to excellence.” — Tania Weiss, Ph.D., CEO, ...
This article is based on a poster originally authored by Yongyang Huang, Ning Guo, Mackenzie Pierce, Leo Chan, Bo Lin and Yi Yang, which was presented at ELRIG Drug Discovery 2024 in affiliation with ...
Tom Congdon (left) is the CEO and Co-Founder of CryoLogyx (Coventry, UK), a University of Warwick (UK) spinout that develops technology for cryopreservation of cell-based assays and novel ...
Fluorescence microscopy offers robust, multi-parametric and scalable analysis of cell level activity in heterogenous populations with spatial and temporal resolution, often critical for effective ...
Slingshot Biosciences, the leader in precision-engineered cell mimic technologies, today announced the launch of TruCytes™ Potency, a new class of biomarker cell mimics specifically designed for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback